Research in Context
Aripiprazole has a favorable risk/benefit ratio in these older adults, most of whom receive treatment in primary care or general medical settings.
• The NNT of aripiprazole of 6.6 is comparable to the NNT in young adults of the two most well-studied augmentation therapies:
lithium NNT= 5
Crossley and Bauer, Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68(6): atypical antipsychotics NNT = 9
Nelson and Papakotsas, Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166(9):980-91 What are second-line options?
• Second line options include: Response (%) Nelson JC, et al. Am J Geriatric Psychiatry. 2008; 16:558-567 * *P < .001. CI = confidence interval; NNT = number needed to treat; OR = odds ratio. Pinquart et al., American Journal of Psychiatry, 163(9):1493 -1501 , 2006 Pinquart, Duberstein, American Journal of Geriatric Psychiatry, 15(8):639-651, 2007 
Meta-Analyses Comparing

Not significant
Recommendations for Psychosocial Interventions in Older Adults
For depression, effective first-line treatments include:
•Behavioral activation -PST -CBT -With or without medications
•For anxiety, first-line treatment is selective serotonin reuptake inhibitor/selective norepinephrine reuptake inhibitor medication.
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Rationale for IRL GREY Study Remission rate: 44% vs 29%
• NNT = 6.6
• For perspective:
-NNT 13 for acute pharmacotherapy in LLD -NNT 5 for Li augmentation in TRD -NNT 9 for atypical antipsychotics in TRD Cardiometabolic outcomes
• Participants randomized to aripiprazole showed greater increase in body weight, but not in total body fat than those randomized to placebo
• There were no differences between groups in changes in percentage of body fat, total cholesterol, HDL, LDL, triglycerides, glucose, or insulin levels 
Early discontinuation of medication and SAEs
• Aripiprazole discontinuation: 5/91 (5.5%) participants discontinued medication prior to the end of the randomized phase (1 completed suicide; 1 due to jitteriness/akathisia, 1 due to worsening Parkinsonism; and 2 withdrew consent) exact p=0.41
Early discontinuation of medication and SAEs
• Placebo discontinuation: 8/90 (8.9%) participantd discontinued medication (2 due to lack of efficacy; 1 due to worsening Parkinsonism; 2 due to headaches, and 3 withdrew consent) exact p=0.41
Serious Adverse Events
• Aripiprazole SAE: Observed in 4/91 (5%), including completed suicide; hospitalized for congestive heart failure; suffered mild stroke; hospitalized for diverticulitis
• Placebo SAE: 2/90 (2%), including myocardial infarction; hospitalized for vomiting attributed to accidentally taking extra venlafaxine
